Proper dose titration ensures both efficacy and tolerability data are captured
Early rapid loss doesn't always predict long-term outcomes
In a July 2024 retrospective, electronic health record (EHR) study in 41,222 adults with overweight or obesity treated for type 2 diabetes, 81.8% of people receiving tirzepatide (Mounjaro) lost at least 5% of their weight within one year compared to 66.5% of those using semaglutide (Ozempic), a significant difference (which means it did not just happen by chance)
All your medical information and communications are private, secure, and auditable within your patient account, ensuring full confidentiality
Other side effects Very common (may affect more than 1 in 10 people) feeling sick (nausea) this usually goes away over time diarrhoea this usually goes away over time low blood sugar (hypoglycaemia) when this medicine is used with medicines that contain a sulfonylurea or insulin
Endocrinology and Metabolism, 289 (6), E1015E1022